The Efficacy and Safety of Temozolomide in SDH-deficient GIST
NCT05661643 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29
Last updated 2026-04-07
Summary
The goal of this clinical trial is to investigate the efficacy and safety of temozolomide in SDH deficiency GIST patients.
Conditions
Interventions
- DRUG
-
Temozolomide capsule
Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)
Sponsors & Collaborators
-
Asan Medical Center
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-28
- Primary Completion
- 2026-12-01
- Completion
- 2027-12-31
Countries
- South Korea
Study Locations
More Related Trials
-
Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy
NCT03061708 ·Status: TERMINATED ·Phase: PHASE2
-
Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
NCT05132738 ·Status: UNKNOWN ·Phase: NA
-
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
NCT03165721 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy
NCT03082833 ·Status: TERMINATED ·Phase: PHASE2
-
Second-line Pharmacotherapy Patterns and Outcomes of Advanced Gastrointestinal Stromal Tumor: A Real-world Study
NCT05440357 ·Status: RECRUITING
-
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
NCT06238167 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.
NCT02736552 ·Status: WITHDRAWN ·Phase: PHASE3
-
S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma
NCT02495493 ·Status: COMPLETED ·Phase: PHASE2
-
Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
NCT02009423 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy
NCT03086291 ·Status: UNKNOWN ·Phase: PHASE1
-
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST
NCT02776878 ·Status: UNKNOWN ·Phase: NA
-
Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer
NCT01095120 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400 ·Status: RECRUITING ·Phase: PHASE3
-
A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer
NCT00512681 ·Status: COMPLETED ·Phase: PHASE2
-
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy
NCT02448329 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer
NCT00587145 ·Status: UNKNOWN ·Phase: PHASE2
-
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
NCT03944304 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT04282980 ·Status: COMPLETED ·Phase: PHASE2
-
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
NCT05687357 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy
NCT02949947 ·Status: TERMINATED ·Phase: PHASE2
-
PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma
NCT02615730 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
NCT04106024 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety Study of Combined Systemic and Intraperitoneal Chemotherapy to Treat Stomach Cancer
NCT01525771 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
NCT05489237 ·Status: RECRUITING ·Phase: PHASE1
-
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
NCT06885034 ·Status: RECRUITING ·Phase: PHASE1/PHASE2